Page 2476 - Williams Hematology ( PDFDrive )

2447
2446 Index Index 2447

thrombocytopenia in, 1252–1254, 1253t, adult T-cell leukemia/lymphoma and, for cytoreduction in chronic myelogenous
2009 1573, 1694, 1700 leukemia, 1450
thrombotic microangiopathy in, 1252 epidemiology, 1573 for essential thrombocythemia,
transfusion-related transmission of, 2370t transfusion-related, 2370t 1313–1314, 1313t, 1314t, 2081
treatment HUMARA (human androgen-receptor gene), for hyperleukocytosis, 1286, 1397
antiretroviral therapy, 1242, 1242t 883 megaloblastic anemia and, 605, 606t
gene therapy, 440–441, 454, 1243 Humoral immunity for myelodysplastic syndromes, 1362
Human leukocyte antigen (HLA), neonatal, 108–109 pharmacology, 325
2353–2356. See also Major primary myelofibrosis and, 1325 for polycythemia vera, 1298–1299,
histocompatibility complex (MHC) in T-cell large granular lymphocytic 1298t
antibodies, 2356, 2385 leukemia, 1563 for primary myelofibrosis, 1329
class I, 2353–2354, 2354t Humoral mediators, 268 for sickle cell disease, 774, 774t, 775f
class II, 2353, 2354t Huntington disease-like 2 (HDL2) disorder, Hydroxyzine, for mastocytosis, 976
clinical applications, 2356 682 Hyperactivity syndromes, iron deficiency
definition, 2353 Hurler syndrome, 22f and, 632
genetics, 2353, 2355, 2355f HUS. See Hemolytic uremic syndrome Hyperbilirubinemia, 832, 857
nomenclature, 2354–2355 (HUS) Hypercalcemia
structure and function, 2353–2354, 2354f Hyaladherins, 67t, 68 in acute myelogenous leukemia, 1287,
tumor-derived molecules, 421 Hyaluronan, 266–267 1383
typing, 2355–2356 Hybrid capture, 159–160, 159f in chronic myelogenous leukemia,
Human leukocyte antigen (HLA)-A2, 1617, Hybrid leukemia, 1386 1448–1449
2354f Hydroa aestivale, 890 in myeloma, 1502, 1744
Human leukocyte antigen (HLA) class II Hydroa vacciniforme-like lymphoma, HyperCVAD regimen
receptors, 1055–1056 1499t for acute lymphoblastic leukemia, 1516
Human leukocyte antigen (HLA)-DP, 1055, Hydrocytosis, hereditary, 682t, 683–684 for Burkitt lymphoma, 1675t, 1676
1700 Hydrogen peroxide, 284t, 286 for hepatosplenic T-cell lymphoma, 1701
Human leukocyte antigen (HLA)-DQ, 1055, in drug-induced hemolysis, 706, 707f for HIV-associated lymphoma, 1245
1700 in erythrocyte metabolism, 698–699 Hyperdiploidy, 175t, 183, 222t, 224t
Human leukocyte antigen (HLA)-DQ2, 1699 5-Hydroperoxyeicosatetraenoic acid Hypereosinophilic syndromes. See also
Human leukocyte antigen (HLA)-DR, 948, (5-HPETE), 289 Chronic eosinophilic leukemia
1055, 1647 12-Hydroperoxyeicosatetraenoic acid eosinophilic fasciitis, 518, 960
in adult T-cell leukemia/lymphoma, 1700 (12-HPETE), 1877 eosinophilic granulomatosis with
in mycosis fungoides, 1682 15-Hydroperoxyeicosatetraenoic acid polyangiitis, 959–960
Human leukocyte antigen (HLA)-DR2, 515 (15-HETE), 952 eosinophilorrachia, 960
Human leukocyte antigen (HLA)-DR15, Hydrops fetalis, 849, 851. See also eosinophiluria, 960
1359 Hemoglobin Bart’s hydrops fetalis history and definition, 1469
Human neutrophil antigens (HNAs), syndrome idiopathic, 957–959
2356–2359, 2357t Hydroxychloroquine neoplasms and, 959
antibodies, 2358–2359 for antiphospholipid syndrome, 2245 toxic oil syndrome, 959
HNA-1, 2356–2357 for porphyria cutanea tarda, 908 Hyperfibrinolysis, 2192, 2194
HNA-2, 2357–2358 Hydroxycobalamin, 589 Hyperglycemia, 1519, 2203
HNA-3, 2358 Hydroxyethyl starch, 2079 Hyperhemolytic crisis, in sickle cell disease,
HNA-4 and HNA-5, 2358 2-Hydroxyglutarate (2-HG), 198 767
Human neutrophil peptides. See Defensins Hydroxyl radicals, 284t, 286, 2203 Hyperhomocysteinemia
Human platelet antigens (HPAs), 2359–2362 Hydroxymethylbilane, 891f acquired causes, 2224, 2224t
alloantigens, 2359, 2360–2361t Hydroxymethylbilane synthase. See arterial thromboembolic disease risk and,
clinical importance, 2362 Porphobilinogen deaminase 2227
detection methods, 2361–2362 (PBGD) clinical features, 2222
genetics and structure, 2359 5-Hydroxytryptamine (serotonin), 286t, 289, epidemiology, 2222t, 2224
isoantigens, 2359 1848, 1878–1879 etiology and pathogenesis, 598–599,
in newborn, 108 Hydroxyurea, 325, 336 2224
nomenclature, 2359, 2361 adverse effects, 325, 1313–1314 venous thromboembolism risk and, 2222,
Human Reference Genome, 155 for chronic eosinophilic leukemia, 1470 2224–2225, 2225t, 2226t
Human T lymphotropic virus (human for chronic myelogenous leukemia, 1459 Hyperimmunoglobulin E syndrome (HIES),
T-cell leukemia/lymphoma virus) for chronic myeloproliferative disorders, 1020t, 1026–1027, 1182, 1215t,
(HTLV)-1 infection 2081 1225

Kaushansky_index_p2393-2506.indd 2447 9/21/15 3:22 PM